GLP1R and type 2 diabetes mellitus: In this endeavor, recent successes of sodium glucose cotransporter 2 inhibitor39,40 and glucagon-like peptide-1 receptor agonist41,42 trials in reducing HF admissions in patients with type 2 diabetes show early promise.